CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Ixazomib Citrate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01718743
NCT01718743Phase 2Completed
CompareCT.gov

Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma

M.D. Anderson Cancer Center·interventional·Posted Oct 31, 2012·Updated Jan 28, 2025

In Brief

A Phase 2 clinical trial evaluating Ixazomib Citrate, Lenalidomide, and 1 other intervention for Hematopoietic Cell Transplantation Recipient and Plasma Cell Myeloma. Completed, enrolled 64 participants across 1 site.

Detailed Summary

This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 31, 2012
Enrollment StartDec 3, 2012
Primary CompletionApr 12, 2023
TodayJul 2, 2026
Enrollment to primary: 10.4 yearsPosted 13.7 years ago

Interventions

Ixazomib Citratedrug

Given PO

Lenalidomidedrug

Given PO

Questionnaire Administrationother

Ancillary studies